Clinical-Stage Products Focused on Novel Targets
At Oncternal, we are advancing first-in-class, novel therapies that address unmet needs for both rare and more common cancers. Our two clinical-stage development compounds are focused on exciting targets that are uniquely expressed within cancer cells. By leveraging pathways not expressed on healthy cells, we aim to inhibit cancer cell growth, while reducing potential harm to healthy cells the body needs. We are already pursuing trials in chronic lymphocytic leukemia and Ewing sarcoma. And, we intend to rapidly broaden our pipeline and invest in the development of these innovative therapies across multiple cancers.
We are recruiting patients
- With CLL for a Phase 1 study of Cirmtuzumab, our anti-ROR1 monoclonal antibody
- With Ewing sarcoma for a Phase 1 study of TK216, our small molecule inhibitor of ets-family transcription factor oncoproteins